Thursday, June 2, 2016

US FDA News: Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars

Reports of severe redness, pain, skin discoloration, blistering, and cracked skin.
Read more: Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars